Researchers looked at 821 people who were exposed to the virus either through their line of worker as a healthcare professional, or from someone at home. That difference was not statistically significant, and "it's also not clinically meaningful", Rajasingham says.
The WHO said hydroxychloroquine trials would restart after a safety review found there was no reason to modify the trial.
Researchers behind a large study on the that examined the risks and benefits of using the anti-malaria drug hydroxychloroquine as a potential treatment for Covid-19 are now posting corrections to the study, after more than 180 scientists expressed concerns over inconsistencies in some of the data used for the research.
"While we are disappointed that this did not prevent COVID-19, we are pleased that we were able to provide a conclusive answer", Boulware said in a university news release.
The results were the latest development in a highly charged medical and political issue - the efficacy of hydroxychloroquine in combating covid-19.
Hundreds of protesters rally in London, Berlin over U.S. death
Floyd was repeatedly telling the officers that he could not breathe until becoming unresponsive. They carried away TVs and other merchandise even as some protesters urged them to stop.
"I think in the setting of post-exposure prophylaxis, it doesn't seem to work", said Sarah Lofgren, an assistant professor at the University of Minnesota who is a co-author of the study. Hydroxychloroquine has always been used for malaria, lupus and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.
It appears a major study published 22nd May in renowned global medical journal The Lancet, which ruled antimalarial drugs touted by Donald Trump as possible COVID-19 treatments could be lethal, was based on data supplied by an obscure analytics company, Surgisphere, which counts a sci-fi writer and exotic model among its staff. Of those who developed COVID-19, 49 had received hydroxychloroquine, while 58 people who received the placebo developed it.
The results are due to be published later Wednesday in the New England Journal of Medicine.
"They said there" was no further benefit to prevent infection among those who also took zinc or vitamin C", which are commonly paired with the antimalarials.
In March, Trump said hydroxychloroquine used in combination with the antibiotic azithromycin had "a real chance to be one of the biggest game changers in the history of medicine" with little evidence to back up that claim.
Boulware said his trial had fewer participants than initially planned because of difficulty enrolling new subjects after the FDA's warning. "And this study stopped or paused a couple of those trials, and changed the narrative around a drug that no one knows if it works or not", he said.